Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 307

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Systematic Review and Meta-analysis of Real-World Adherence to Drug Therapy for Osteoporosis

Kothawala, Prajesh, Badamgarav, Enkhe, Ryu, Seonyoung, Miller, Ross M., Halbert, R.J.·2007·Mayo Clinic Proceedings
DOI 10.1016/s0025-6196(11)61093-8
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0025-6196(11)61093-8

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 46

  1. Cranney, 2002, Meta-analyses of therapies for postmenopausal osteoporosis, IX: summary of meta-analyses of therapies for postmenopausal osteoporosis, Endocr Rev, 23, 570, 10.1210/er.2001-9002 · DOI · Paper page
  2. Siris, 2006, Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases, Mayo Clin Proc, 81, 1013, 10.4065/81.8.1013 · DOI · Paper page
  3. Cramer, 2005, Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis, Curr Med Res Opin, 21, 1453, 10.1185/030079905X61875 · DOI · Paper page
  4. Kayser, 2001, Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen, Menopause, 8, 328, 10.1097/00042192-200109000-00006 · DOI
  5. Huybrechts, 2005, Assessment of compliance with osteoporosis treatment and its consequences in a managed care population, Bone, 38, 922, 10.1016/j.bone.2005.10.022 · DOI · Paper page
  6. Papaioannou, 2007, Patient adherence to osteoporosis medications: problems, consequences and management strategies, Drugs Aging, 24, 37, 10.2165/00002512-200724010-00003 · DOI · Paper page
  7. Cramer, 2007, A systematic review of persistence and compliance with bisphosphonates for osteoporosis, Osteoporos Int, 18, 1023, 10.1007/s00198-006-0322-8 · DOI · Paper page
  8. Dezii, 2001, Persistence with drug therapy: a practical approach using administrative claims data, Manag Care, 10, 42
  9. Gold, 2006, Review of adherence to medications for the treatment of osteoporosis, Curr Osteoporos Rep, 4, 21, 10.1007/s11914-006-0011-8 · DOI
  10. Weycker, 2006, Compliance with drug therapy for postmenopausal osteoporosis, Osteoporos Int, 17, 1645, 10.1007/s00198-006-0179-x · DOI
  11. Recker, 2005, Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women, Mayo Clin Proc, 80, 856, 10.4065/80.7.856 · DOI
  12. Segal, 2003, Compliance of osteoporotic patients with different treatment regimens, Isr Med Assoc J, 5, 859
  13. Penning-van Beest, 2006, Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis, Clin Ther, 28, 236, 10.1016/j.clinthera.2006.01.002 · DOI
  14. Lo, 2006, Persistence with weekly alendronate therapy among postmenopausal women, Osteoporos Int, 17, 922, 10.1007/s00198-006-0085-2 · DOI
  15. Solomon, 2005, Compliance with osteoporosis medications, Arch Intern Med, 165, 2414, 10.1001/archinte.165.20.2414 · DOI · Paper page
  16. Cauza, 2004, Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis, J Clin Pharm Ther, 29, 431, 10.1111/j.1365-2710.2004.00584.x · DOI
  17. Cuddihy, 2004, A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture, Osteoporos Int, 15, 695, 10.1007/s00198-004-1597-2 · DOI
  18. Filipponi, 1996, Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial, Bone, 18, 179, 10.1016/8756-3282(95)00442-4 · DOI
  19. McCombs, 2004, Compliance with drug therapies for the treatment and prevention of osteoporosis, Maturitas, 48, 271, 10.1016/j.maturitas.2004.02.005 · DOI · Paper page
  20. Ryan, 1992, Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis, Br J Obstet Gynaecol, 99, 325, 10.1111/j.1471-0528.1992.tb13732.x · DOI
  21. Steel, 2003, Factors affecting long-term adherence to hormone replacement therapy after screening for osteoporosis, Climacteric, 6, 96, 10.1080/cmt.6.2.96.103 · DOI
  22. Turbi, 2004, Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study, Clin Ther, 26, 245, 10.1016/S0149-2918(04)90023-9 · DOI
  23. Yood, 2003, Compliance with pharmacologic therapy for osteoporosis, Osteoporos Int, 14, 965, 10.1007/s00198-003-1502-4 · DOI
  24. Pickney, 2005, Correlation between patient recall of bone densitometry results and subsequent treatment adherence, Osteoporos Int, 16, 1156, 10.1007/s00198-004-1818-8 · DOI
  25. Watts, 1999, Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate, Bone, 24, 65, 10.1016/S8756-3282(98)00144-6 · DOI
  26. Hamilton, 2003, Tolerability and compliance with risedronate in clinical practice, Osteoporos Int, 14, 259, 10.1007/s00198-002-1370-3 · DOI
  27. Caro, 2004, The impact of compliance with osteoporosis therapy on fracture rates in actual practice, Osteoporos Int, 15, 1003, 10.1007/s00198-004-1652-z · DOI · Paper page
  28. Carnevale, 2005, Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey, Osteoporos Int, 17, 478, 10.1007/s00198-005-0010-0 · DOI
  29. Zafran, 2005, Incidence and causes for failure of treatment of women with proven osteoporosis, Osteoporos Int, 16, 1375, 10.1007/s00198-005-1838-z · DOI
  30. Papaioannou, 2003, Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database, Osteoporos Int, 14, 808, 10.1007/s00198-003-1431-2 · DOI
  31. Storm, 1996, Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis, J Rheumatol, 23, 1560
  32. Hejdova, 2005, Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women: an observational study, Pharm World Sci, 27, 149, 10.1007/s11096-005-0014-z · DOI
  33. Emkey, 2006, Improving compliance and persistence with bisphosphonate therapy for osteoporosis, Am J Med, 119, S18, 10.1016/j.amjmed.2005.12.019 · DOI
  34. Gold, 2006, Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses, J Manag Care Pharm, 12, S20, 10.18553/jmcp.2006.12.S6-A.S20 · DOI
  35. Sikka, 2005, Estimating medication persistency using administrative claims data, Am J Manag Care, 11, 449
  36. Brookhart, 2007, Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance, Am J Med, 120, 251, 10.1016/j.amjmed.2006.03.029 · DOI
  37. Avorn, 1998, Persistence of use of lipid-lowering medications: a cross-national study, JAMA, 279, 1458, 10.1001/jama.279.18.1458 · DOI · Paper page
  38. Dezii, 2000, Medication noncompliance: what is the problem?, Manag Care, 9, 7
  39. Beers, 2000, Drugs and the elderly, part 1: the problems facing managed care, Am J Manag Care, 6, 1313
  40. van den Boogaard, 2006, Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study, Curr Med Res Opin, 22, 1757, 10.1185/030079906X132370 · DOI
  41. Weycker, 2007, Compliance with osteoporosis drug therapy and risk of fracture, Osteoporos Int, 18, 271, 10.1007/s00198-006-0230-y · DOI
  42. Bosmans, 2007, Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants, Pharmacoeconomics, 25, 25, 10.2165/00019053-200725010-00004 · DOI
  43. Brunenberg, 2007, Cost effectiveness of an adherence-improving programme in hypertensive patients, Pharmacoeconomics, 25, 239, 10.2165/00019053-200725030-00006 · DOI
  44. Schulgen, 1994, Outcome-oriented cutpoints in analysis of quantitative exposures, Am J Epidemiol, 140, 172, 10.1093/oxfordjournals.aje.a117227 · DOI
  45. Wagner, 2001, Patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence, J Clin Epidemiol, 54, S91, 10.1016/S0895-4356(01)00450-4 · DOI
  46. Steiner, 1997, The assessment of refill compliance using pharmacy records: methods, validity, and applications, J Clin Epidemiol, 50, 105, 10.1016/S0895-4356(96)00268-5 · DOI · Paper page

Cited by

See all 307

Metadata

Authors
Kothawala, P., Badamgarav, E., Ryu, S., Miller, R. M., & Halbert, R. J.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2007-12
Volume
82
Issue
12
Pages
1493-1501
ISSN
0025-6196 (ISSN-L)
DOI
10.1016/s0025-6196(11)61093-8
OpenAlex
W2091246702
Cited by
307
References
8
FWCI
1.45
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.